Abstract
Older adults with comorbidities who are at extreme risk for surgical aortic valve replacement may be appropriate candidates for transcatheter aortic valve replacement (TAVR). We present the 5-year clinical, echocardiographic, and health status outcomes of such patients treated with CoreValve self-expanding supra-annular TAVR. The CoreValve US Extreme Risk Pivotal Trial was a prospective, nonrandomized, single-arm clinical trial of TAVR at 41 sites in the United States. The primary outcome was all-cause mortality or major stroke. Secondary outcomes included echocardiographic parameters and patient-reported health status, assessed with the Kansas City Cardiomyopathy Questionnaire. Between February 2011 and August 2012, 639 patients with severe aortic stenosis at extreme surgical risk underwent attempted TAVR (mean age 82.8±8.4 years, 53% women, mean Society of Thoracic Surgeons Predicted Risk of Mortality 10.4±5.6%, 77% iliofemoral access). The 5-year Kaplan-Meier rate of death or major stroke was 72.6% ([95% CI, 68.4%–76.7%]; death 71.6%, major stroke 11.5%), with no significant differences according to access site. Among patients who survived 5 years, mean transvalvular gradient was 7.5±5.9 mm Hg, and 3.1% had moderate or sever...Continue Reading
References
Mar 1, 1996·Medical Care·J WareS D Keller
Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Oct 8, 2005·American Heart Journal·John SpertusUNKNOWN Cardiovascular Outcomes Research Consortium
Oct 22, 2010·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER Trial Investigators
Jan 11, 2011·European Heart Journal·Martin B LeonPatrick W Serruys
Oct 5, 2011·Circulation·Matthew R ReynoldsUNKNOWN Placement of Aortic Transcatheter Valves (PARTNER) Investigators
Mar 27, 2012·The New England Journal of Medicine·Raj R MakkarUNKNOWN PARTNER Trial Investigators
Jun 26, 2012·Journal of the American College of Cardiology·Lutz BuellesfeldStephan Windecker
Dec 12, 2012·Circulation. Heart Failure·Suzanne V ArnoldDavid J Cohen
Dec 29, 2013·Circulation·Marina UrenaJosep Rodés-Cabau
Mar 25, 2014·Journal of the American College of Cardiology·Jeffrey J PopmaUNKNOWN CoreValve United States Clinical Investigators
Mar 20, 2015·Lancet·Samir R KapadiaUNKNOWN PARTNER trial investigators
Jun 10, 2015·Journal of the American College of Cardiology·Michael J ReardonJeffrey J Popma
Aug 22, 2015·JACC. Cardiovascular Interventions·Suzanne V ArnoldUNKNOWN CoreValve US Pivotal Trial Investigators
Nov 12, 2016·JACC. Cardiovascular Interventions·Opeyemi O FadahunsiAnthony Donato
Mar 18, 2017·The New England Journal of Medicine·Michael J ReardonUNKNOWN SURTAVI Investigators
Jun 29, 2017·JAMA Cardiology·Suzanne J BaronUNKNOWN PARTNER 2 Investigators
Dec 11, 2017·American Heart Journal·Suzanne J BaronUNKNOWN US CoreValve Investigators
Sep 27, 2018·Journal of the American College of Cardiology·Thomas G GleasonUNKNOWN CoreValve U.S. Pivotal High Risk Trial Clinical Investigators
Mar 19, 2019·The New England Journal of Medicine·Jeffrey J PopmaUNKNOWN Evolut Low Risk Trial Investigators
Jan 12, 2020·European Heart Journal. Quality of Care & Clinical Outcomes·Suzanne V ArnoldDavid J Cohen